“South Africa’s rollout of lenacapavir, a groundbreaking long-acting HIV prevention injection, has hit major obstacles in Gauteng, with patients in Pretoria reporting being turned away due to limited availability. The setback highlights systemic weaknesses in medicine distribution and threatens to undermine progress in HIV prevention efforts.”
On July 1, 2026, South Africa’s ambitious rollout of lenacapavir (LEN), hailed as a revolutionary HIV prevention tool, faced significant challenges in Gauteng province. Patients in Pretoria reported being denied access to the injection, despite government promises of widespread availability. This development has sparked concern among public health experts, activists, and affected communities, raising questions about the country’s readiness to deliver on its HIV prevention commitments.
Background: Lenacapavir’s Promise
Lenacapavir is a long-acting injectable antiretroviral drug designed to prevent HIV infection. Unlike daily oral pre-exposure prophylaxis (PrEP), LEN requires administration only once every six months, offering a more convenient and potentially more effective solution for populations at high risk of HIV. Clinical trials demonstrated strong efficacy, and South Africa was among the first countries in Africa to approve its rollout, positioning itself as a leader in HIV prevention innovation.
The Rollout Plan
The National Department of Health announced in June 2026 that Gauteng would serve as a pilot province, with 360 designated sites prepared to administer LEN. The plan aimed to prioritize key populations, including sex workers, men who have sex with men, and young women, who remain disproportionately affected by HIV. The government emphasized that LEN would be available free of charge at public clinics, supported by international donors and local health organizations.
The Challenges in Pretoria
Despite these commitments, patients in parts of Pretoria reported being turned away when seeking the injection. Some clinics cited supply shortages, while others admitted logistical delays in training staff and preparing facilities. Reports from Health-e News revealed that only a fraction of the designated sites were fully operational, leaving many patients frustrated and vulnerable.
Voices from the Ground
Keletso Mkhwanazi, a health activist in Pretoria, described the situation as “deeply disappointing.” “We were told LEN would be a game-changer, but now people are being sent home without protection. This undermines trust in the health system,” she said. Patients echoed similar sentiments, with some expressing fear of increased HIV risk due to the delays.
Systemic Weaknesses
The rollout challenges highlight broader systemic issues in South Africa’s health system. Experts point to chronic underfunding, staff shortages, and weak supply chain management as recurring problems. These weaknesses have previously affected the distribution of other essential medicines, including antiretrovirals and tuberculosis drugs. The LEN rollout appears to be the latest casualty of these structural deficiencies.
Government Response
The Gauteng Department of Health acknowledged the problems, attributing them to “teething issues” in the early stages of rollout. Officials promised that supply chains would stabilize within weeks and urged patients to remain patient. However, critics argue that such assurances are insufficient, given the urgency of HIV prevention and the high stakes involved.
Implications for HIV Prevention
South Africa remains one of the countries hardest hit by HIV, with over 7.5 million people living with the virus. The introduction of LEN was seen as a critical step toward reducing new infections, particularly among young women, who account for a disproportionate share of new cases. Delays in rollout risk undermining these efforts, potentially leading to preventable infections and increased healthcare costs.
International Perspective
Globally, LEN has been hailed as a breakthrough in HIV prevention. Countries such as the United States and Brazil have already begun integrating LEN into their prevention programs, with early reports showing promising uptake. South Africa’s struggles therefore stand in stark contrast, raising concerns about whether resource-limited settings can fully capitalize on medical innovations without addressing systemic weaknesses.
Civil Society and Advocacy
Civil society organizations have called for greater transparency and accountability in the LEN rollout. Groups such as the Treatment Action Campaign (TAC) have demanded detailed reports on supply chain management and urged the government to involve community stakeholders in problem-solving. Activists argue that without community engagement, trust in the health system will continue to erode.
Looking Ahead
The LEN rollout represents both a challenge and an opportunity for South Africa. If the government can resolve logistical issues quickly, LEN could still fulfill its promise as a transformative HIV prevention tool. However, failure to address systemic weaknesses risks turning a medical breakthrough into a missed opportunity.
Conclusion
The stumbling rollout of lenacapavir in Gauteng underscores the urgent need for health system reform in South Africa. While LEN offers unprecedented potential in HIV prevention, its success depends on effective distribution, community trust, and sustained political commitment. For now, patients in Pretoria remain caught between hope and frustration, waiting for a promised injection that could change their lives.
